Phillip A. Sharp

In early 2020, Phillip A. Sharp co-authored a highly influential paper on RNA nanotechnology, a field that explores the use of RNA molecules to construct nanoscale structures for use in medicine and biotechnology. His work illustrates the potential of RNA as a versatile tool for precision therapeutics and diagnostics, emphasizing its importance in modern science.

On April 25, 2013, Phillip A. Sharp was awarded the National Medal of Science by President Barack Obama. The award recognized his distinguished contributions to science, particularly his work in molecular biology and biotechnology, including his discovery of RNA splicing and his role in founding cutting-edge biotech companies.

In 2006, Phillip A. Sharp was appointed as the head of the Massachusetts Institute of Technology (MIT) Cancer Center, where he led initiatives focusing on understanding cancer at a molecular level. Under his leadership, the Center pursued innovative research projects aimed at uncovering the mechanisms underlying cancer development and progression.

In November 2004, Phillip A. Sharp co-founded Alnylam Pharmaceuticals, focusing on the development of RNA interference (RNAi) therapies. RNAi is a revolutionary approach to gene therapy that harnesses natural cellular pathways to silence specific genes. This venture highlighted Sharp's commitment to translating RNA science into medical applications to treat diseases.

In June 2000, Phillip A. Sharp was appointed as an Institute Professor at the Massachusetts Institute of Technology (MIT), a prestigious title recognizing his exceptional contributions to molecular biology. As an Institute Professor, Sharp continued to drive innovation in research, focusing on the intersection of biology and engineering, while mentoring future generations of scientists.

On October 11, 1993, Phillip A. Sharp was awarded the Nobel Prize in Physiology or Medicine, shared with Richard J. Roberts, for their discovery of split genes. This was a transformative moment in biology, providing a new understanding of the genetic structure and its transcription in higher organisms, and how genetic information is transmitted within cells.

In 1985, Phillip A. Sharp co-founded Biogen, a biotechnology company, which became one of the world's leading biotech firms. Biogen focused on discovering and developing innovative therapies for diseases with high unmet needs. Sharp's involvement in Biogen helped bridge the gap between academic discoveries and therapeutic applications, fostering innovation in drug development.

In the late 1970s, Phillip A. Sharp and his laboratory made the groundbreaking discovery of RNA splicing, in which non-coding regions of RNA are excised and coding regions are fused together. This discovery challenged the existing views of gene structure in eukaryotic cells and revolutionized our understanding of gene expression.

In 1972, Phillip A. Sharp earned his PhD in chemistry from the University of Illinois at Urbana-Champaign, where he studied the chemical interactions related to the structure and function of DNA. This foundational education set the stage for his significant contributions to the field of molecular biology, specifically in the area of RNA splicing.

Phillip A. Sharp, renowned molecular biologist and Nobel Prize laureate, was born on June 6, 1944, in Falmouth, Kentucky, USA. He grew up on a family farm and attended a rural high school, before excelling in his studies and attending college. Sharp is best known for his groundbreaking work on RNA splicing, a discovery that has had profound implications in molecular biology.